HIMS Stock Slides After Amazon Escalates GLP-1 War With Ozempic — AI Healthcare Bets In Focus Ahead Of Earnings

• Amazon said customers can access real-time medication availability, transparent pricing, and same-day delivery.
• Citi previously noted that Amazon’s healthcare model still differs from subscription-based telehealth platforms like Hims.
• Hims recently launched Labs AI, an AI-powered health assistant that analyzes biomarker trends, lab tests and health risks.

Shares of Hims & Hers Health, Inc. (HIMS) slipped 5% on Thursday after Amazon Pharmacy expanded same-day access to Novo Nordisk’s oral Ozempic treatment, escalating competition in the GLP-1 market just as Hims ramps up its AI healthcare push ahead of earnings next week.

HIMS stock ended Thursday at $25.65, with shares poised to log their second straight week of losses after a decline of over 6% so far this week. 

Amazon Expands Ozempic Access

The latest move from Amazon broadens access to the only FDA-approved oral GLP-1 therapy for Type 2 diabetes. Amazon said customers who have been prescribed the oral Ozempic pill can now access real-time medication availability, transparent pricing, and same-day prescription delivery through Amazon Pharmacy, regardless of Prime membership status. 

The company also plans to introduce licensed pharmacist-supported kiosk pickup at select One Medical clinics, allowing patients to receive their medications within minutes of their appointments instead of waiting in pharmacy lines.

Amazon said that the oral GLP-1 treatment will initially be available via same-day delivery in nearly 3,000 cities and towns, then expand to 4,500 locations by the end of the year. Pricing for insured patients starts as low as $25 monthly, while cash-pay customers can access the treatment starting at $149 per month after manufacturer-sponsored discounts.

The rollout comes after Amazon recently launched its GLP-1 management platform through One Medical, which integrates primary care, pharmacy access, virtual consultations, and metabolic monitoring into a single platform for patients with obesity and diabetes.

The move adds fresh pressure on telehealth firms like Hims, which has shifted toward branded GLP-1 therapies after the FDA tightened regulations on compounded Semaglutide and Tirzepatide products. Hims already offers branded treatments including Wegovy, Ozempic, Zepbound and Mounjaro through partnerships with Novo Nordisk and Eli Lilly. CEO Andrew Dudum previously said that the company had already started shipping Novo Nordisk medicines and expects to exceed a run rate of 100,000 Wegovy prescriptions per month.

While Amazon’s Ozempic rollout addresses some earlier concerns around limited GLP-1 access, Citi previously noted that the company’s model still differs from subscription-based telehealth platforms like Hims, particularly around continuous care, diagnostics and long-term patient involvement. 

AI Healthcare Push Gains Momentum

Meanwhile, Hims has been pushing its healthcare and AI strategy ahead of its earnings next week. The company on Thursday launched Labs AI, an AI-based health assistant embedded into the Hims & Hers platform that helps customers better understand lab tests, biomarker trends and health risks.

According to the company, Labs AI analyzes up to 130 biomarkers alongside medical history, lifestyle information, and longitudinal health trends to generate personalized health insights. The platform uses curated medical protocols and clinician-designed safeguards rather than relying on information from the open internet. The system can also answer follow-up questions on heart health, metabolism, testosterone levels and other wellness issues.

Dudum said on X that “Trying to decipher complex lab results can be confusing at best and scary at worst,” Dudum said. Investor interest in Hims’ diagnostics plans also increased recently after Dudum expressed interest in a company that claims it can predict heart attacks from blood tests with 86% accuracy.

HIMS Q1 Preview

The company’s earnings report due on Monday will offer investors clues on whether newer healthcare categories and AI-driven offerings can offset intensifying competition and slowing profitability in the GLP-1 market.

According to Fiscal AI estimates, analysts expect quarterly revenue of $616.9 million, up from $538.6 million a year ago. However, earnings before interest, taxes, depreciation, and amortization (EBITDA) are projected to decline to $45 million from $61.6 million last year, while earnings per share (EPS) are expected to fall to $0.01 from $0.12 a year ago. 

Koyfin data shows a 12-month average price target of $26.04, implying a modest 2% upside from current levels. Among 16 analysts covering the stock, three rate it “Strong Buy,” one rates it “Buy,” while 12 maintain “Hold” ratings.

Beyond GLP-1s, Hims has been aggressively expanding into hormone health and peptides. The company recently launched Testosterone Rx+, a once-daily treatment combining Enclomiphene with zinc, vitamins and L-arginine to naturally increase testosterone levels while maintaining fertility. 

Hims has also expanded into women’s hormone health with menopause and perimenopause treatments, while also bracing for potential future peptide-based therapies pending upcoming FDA discussions around compounding regulations.

How Do Retail Traders Feel About HIMS?

On Stocktwits, retail sentiment for HIMS was ‘bearish’ amid ‘extremely low’ message volume.

One user said, “$HIMS has the potential to be the best blend of Healthcare and AI.. people do not fully understand the value of real world data wrapped in AI... it is HUGE..”

Another user said, “all of this because you can get GLP1 through Amazon? Who cares. Thats like $HIMS won’t work because there’s Walgreens and CVS.”

HIMS stock has declined 51% over the past year. 

For updates and corrections, email newsroom[at]stocktwits[dot]com.

Read Next: CAPR Stock Sinks After-Hours: Capricor Launches Legal Fight Over DMD Therapy Rollout Ahead Of FDA Review